Sugi Predict

Sugi Predict / Compounds / SCHEMBL2446479

SCHEMBL2446479

SCHEMBL2446479

O=C(Nc1ccccc1)C1CCCNC1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.66
▸ F10 P00742 1/20 0.60
▸ GAA P10253 2/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ MAPT P10636 1/20 0.55
▸ GFER P55789 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ ULK1 O75385 1/20 0.55
▸ JAK3 P52333 1/20 0.54
▸ TNKS O95271 1/20 0.53
▸ TNKS2 Q9H2K2 1/20 0.53
▸ KHK P50053 1/20 0.53
▸ SLC6A1 P30531 2/20 0.51
▸ SLC6A11 P48066 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ SLC6A13 Q9NSD5 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ GLA P06280 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1318166 1.00 HPGD (0.66) HPGDF10GAAMEN1MAPT
SCHEMBL1318173 1.00 HPGD (0.66) HPGDF10GAAMEN1MAPT
Hydrochloric Acid SCHEMBL4033476 0.98 HPGD (0.64) HPGDF10GAAMEN1MAPT
SCHEMBL1318504 0.90 HPGD (0.60) HPGDF10GAAMEN1MAPT
SCHEMBL14505992 0.90 HPGD (0.60) HPGDF10GAAMEN1MAPT
Hydrochloric Acid SCHEMBL1320464 0.89 HPGD (0.58) HPGDF10GAAMEN1MAPT
SCHEMBL4564743 0.86 ULK1 (0.64) HPGDF10GAAMAPTKMT2A
SCHEMBL1552756 0.85 ULK1 (0.56) HPGDF10ULK1TNKSTNKS2
SCHEMBL2451482 0.85 ULK1 (0.56) ULK1POLB
SCHEMBL2449552 0.85 ULK1 (0.56) F10KMT2AULK1TNKSTNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4249475-A1 COMPOUND HAVING INHIBITORY ACTIVITY AGAINST O-GLCNACASE AND USE THEREOF MEDIFRON DBT INC. (KR) 2023-09-27 — — EP claimed
US-20230312542-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-05 — — US disclosed
EP-4129402-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2023-02-08 — — EP disclosed
CN-115298173-A Hydroxypyrrolidine derivatives and medical use thereof 田边三菱制药株式会社 2022-11-04 — — CN disclosed
US-11306078-B2 Piperidine CXCR7 receptor modulators IDORSIA PHARMACEUTICALS LTD. (CH) 2022-04-19 — — US disclosed
US-20200131125-A1 ARYL-PIPERIDINE DERIVATIVES ARTAX BIOPHARMA INC. 2020-04-30 — — US disclosed
EP-2245014-B1 UREA DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE BOEHRINGER INGELHEIM INT (DE) 2011-11-02 — — EP disclosed
EP-2362775-A1 CHEMICAL COMPOUNDS GlaxoSmithKline LLC (US) 2011-09-07 — — EP disclosed
US-20110028445-A1 Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-03 — — US disclosed
WO-2010120854-A1 CHEMICAL COMPOUNDS GLAXOSMITHKLINE LLC (US) 2010-10-21 — — WO disclosed
US-20030050309-A1 Ligands for monoamine receptors and transporters, and methods of use thereof SEPRACOR INC. 2003-03-13 — — US disclosed
WO-2002069895-A2 HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF SEPRACOR, INC. (US) 2002-09-12 — — WO disclosed
WO-2002022572-A2 LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) SEPRACOR, INC. (US) 2002-03-21 — — WO disclosed
EP-1187810-A2 HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE SEPRACOR, INC. (US) 2002-03-20 — — EP disclosed
US-20020016337-A1 Heterocyclic analgesic compounds and methods of use thereof SEPRACOR INC. 2002-02-07 — — US disclosed
WO-2001092226-A1 HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF SEPRACOR, INC. (US) 2001-12-06 — — WO disclosed
WO-2000071518-A2 HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE SEPRACOR, INC. (US) 2000-11-30 — — WO disclosed
US-6080743-A AS CHEMICAL INTERMEIDATES FOR PREPARING DRUGS NOVARTIS AG (CH) 2000-06-27 — — US disclosed
EP-0853617-A1 NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES Novartis AG (CH) 1998-07-22 — — EP disclosed
WO-1997008155-A1 NOVEL 2,3-DIOXO-1,2,3,4-TETRAHYDRO-QUINOYXALINYL DERIVATIVES NOVARTIS AG (CH) 1997-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028445-A1 Urea derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use XDH, HSD11B1, HSD3B1 HPGD 83/4885F10 2841/4885GAA 387/4885
US-20030050309-A1 Ligands for monoamine receptors and transporters, and methods of use thereof SLC6A2, OPRL1, SLC18A2 HPGD 428/4885F10 3114/4885GAA 238/4885
US-11306078-B2 Piperidine CXCR7 receptor modulators CXCR1, CXCR5, ACKR3 HPGD 1895/4885F10 4352/4885GAA 4819/4885
US-20200131125-A1 ARYL-PIPERIDINE DERIVATIVES CD4, CD2, CCR1 HPGD 1870/4885F10 3220/4885GAA 1712/4885
US-20230312542-A1 HYDROXYPYRROLIDINE DERIVATIVE AND MEDICINAL APPLICATION THEREOF VHL, MDM2, NEDD4 HPGD 2066/4885F10 4701/4885GAA 1563/4885
US-20020016337-A1 Heterocyclic analgesic compounds and methods of use thereof OPRL1, TRPV1, OPRK1 HPGD 270/4885F10 3648/4885GAA 4032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.